Drug profile · INN
tafenoquine succinate
KRINTAFEL
tafenoquine succinate (KRINTAFEL) is a unknown. Route of administration: oral. Current US regulatory status: approved.
FDA: approved
US status approved
Patents linked 3
Pipeline programs 5
News articles 0
Drug details — tafenoquine succinate
- US status
- approved
- Class
- —
- Route
- ORAL
- Patents
- 3
- Programs
- 5
- Data quality
- 0.84
Quick answer
tafenoquine succinate (KRINTAFEL) is a unknown. Route of administration: oral. Current US regulatory status: approved.
Key facts
INN tafenoquine succinate
Brand KRINTAFEL
Mechanism Unknown
Route ORAL
Formulation TABLET
Mechanism of action
Unknown
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
Pipeline programs
Related patents
Frequently asked questions
What is tafenoquine succinate?
tafenoquine succinate (KRINTAFEL) is a unknown. Route of administration: oral. Current US regulatory status: approved.
What is the brand name for tafenoquine succinate?
KRINTAFEL is a marketed brand name for tafenoquine succinate. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of tafenoquine succinate?
tafenoquine succinate has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.